Cargando…

Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer

OBJECTIVES: Assess computed tomography texture analysis of patients likely to benefit from nivolumab. MATERIALS & METHODS: Texture analysis was used to quantify heterogeneity within the largest tumor before immunotherapy. Histogram analysis was classified as hyperdense (positive skewness) or hyp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ladwa, Rahul, Roberts, Kate E, O’Leary, Connor, Maggacis, Nicole, O’Byrne, Kenneth J, Miles, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399606/ https://www.ncbi.nlm.nih.gov/pubmed/32774469 http://dx.doi.org/10.2217/lmt-2020-0002

Ejemplares similares

Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab
por: Rajapakse, Aleksandra, et al.
Publicado: (2020)

High-Plex and High-Throughput Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC)
por: Monkman, James, et al.
Publicado: (2020)

Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Pembrolizumab-induced toxic epidermal necrolysis: case report
por: Chow, Kar Ven Cavan, et al.
Publicado: (2022)

Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review
por: Fernandez, Alejandra, et al.
Publicado: (2021)

Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas
por: Sadeghirad, Habib, et al.
Publicado: (2022)

Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer
por: O’Leary, Connor, et al.
Publicado: (2019)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers
por: Săftescu, Sorin, et al.
Publicado: (2021)

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
por: Burgess, Joshua T., et al.
Publicado: (2020)

The Role of Circulating Biomarkers in Lung Cancer
por: Herath, Sayuri, et al.
Publicado: (2022)

First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
por: Barr, Martin P., et al.
Publicado: (2013)

Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature
por: Barr, Martin P., et al.
Publicado: (2020)

Understanding the tumor microenvironment for effective immunotherapy
por: Sadeghi Rad, Habib, et al.
Publicado: (2020)

Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
por: Gamulin, Marija, et al.
Publicado: (2020)

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
por: Brahmer, Julie R., et al.
Publicado: (2023)

The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report
por: Haghpanah, Mahsa, et al.
Publicado: (2022)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

Prognostic Impact of Baseline Neutrophil-to-Eosinophil Ratio in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Therapy in Second or Later Lines
por: Gil, Lucia, et al.
Publicado: (2022)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
por: Zhou, Dongchu, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
por: O’Leary, Connor, et al.
Publicado: (2020)

Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
por: Kapeleris, Joanna, et al.
Publicado: (2020)

Significance of timing of therapeutic line on effectiveness of nivolumab for metastatic renal cell carcinoma
por: Teishima, Jun, et al.
Publicado: (2023)

Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model
por: Baird, Anne-Marie, et al.
Publicado: (2016)

Immune Checkpoint Inhibitors in Cancer Therapy
por: Shiravand, Yavar, et al.
Publicado: (2022)

Nucleolar caspase-2: Protecting us from DNA damage
por: O’Byrne, Kenneth J., et al.
Publicado: (2017)

How to use CT texture analysis for prognostication of non-small cell lung cancer
por: Miles, Kenneth A.
Publicado: (2016)

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)
por: Hellmann, Matthew, et al.
Publicado: (2015)

Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
por: Padrón, Lacey J., et al.
Publicado: (2022)

A real-world experience of second-line nivolumab in mesothelioma patients during the COVID-19 pandemic
por: Church, Matt, et al.
Publicado: (2021)

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma
por: Di Marco, Lorenza, et al.
Publicado: (2023)

Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage
por: Ganeshan, Balaji, et al.
Publicado: (2010)

Metastatic ovarian carcinoma presenting as an incarcerated femoral hernia
por: Beecher, Suzanne M., et al.
Publicado: (2015)

Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study
por: Chung, Christine H., et al.
Publicado: (2021)

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)

Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2016)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
por: Oro-Ayude, Marcos, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5gajdu7d8h5sic437qggmsghn8